Analyst meeting In the fiscal year ending September 30, 2014 2557 (2014) pharmaceutical organization has net profits after cost of goods sold operating expenses and a share of profit (loss) from investments in a joint venture from income from operations, which are shown in the financial statement shows investments in accordance with how the shelterbelt and had been approved by the Office of arms silver examination (stream d.) are quoted in 1, 003.56 million. Reduced from a year ago, 97.56 million. 8.86 percent
การแปล กรุณารอสักครู่..